相关实验视频
Updated: Feb 26, 2026

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
36.1K
在HeartMate 3左心室辅助装置植入后的十年后的结果
Jasmin S Hanke1, Günes Dogan2, Ali S Merzah2
1Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany - hanke.jasmin@mh-hannover.de.
The Journal of cardiovascular surgery
|February 25, 2026
概括
该HeartMate 3左心室辅助装置 (LVAD) 显示在10年内62.5%的存活率. 这项研究强调了使用LVADs的心力衰竭患者的优秀长期结果.
科学领域:
- 心血管医学 心血管医学
- 医疗器械 医疗器械
- 手术技术 手术技术
背景情况:
- 该HeartMate 3 (HM3) 左心室辅助装置 (LVAD) 在2014年首次植入.
- 这项研究为HM3设备提供了最长的单中心随访数据.
- 专注于HM3植入后的长期生存率和不良事件.
研究的目的:
- 为了评估植入HeartMate 3 LVAD的患者的10年生存率.
- 评估与长期HM3支持相关的不良事件的发生率和类型.
- 在现实临床环境中分析HM3设备的整体性能和结果.
主要方法:
- 2014年接受HM3 LVAD植入的心力衰竭患者的分析.
- 主要终点:10年生存率.
- 二级终点:对不良事件的评估,对心脏移植 (HTx) 的生存率进行审查.
主要成果:
- 总共包括8名患者,平均支持持续时间为6.4年.
- 10年生存率为62.5% (5/8患者).
- 没有发生血栓,中风或技术故障;然而,50%需要对外流移植压缩进行修改,75%经历了传动线感染.
结论:
- HM3 LVAD表现出优异的长期结果,其10年生存率为62.5%.
- 该设备没有显示任何技术故障,血红相容性问题的发生率很低.
- 在精选的心力衰竭患者中及时和适当地使用LVAD导致了出色的结果.
相关概念视频
Cardiomyopathy V: Interprofessional Care
520
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
520
Cardiomyopathy II: Dilated Cardiomyopathy
649
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
649
Cardiomyopathy III: Hypertrophic Cardiomyopathy
555
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
555
Mitral Stenosis III: Medical Management
358
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
358
Cardiac Catheterization III: Left Heart Catheterization
877
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
877
Heart Failure VI: Adjunct Therapies
442
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
442

